Quantcast
Browsing all 3012 articles
Browse latest View live

Jeb Keiper steps down from Nimbus CEO post, business chief to take over

Nimbus Therapeutics is getting a new CEO after more than six years, as Jeb Keiper passes the baton to Abbas Kazimi. Keiper spent over a decade at Nimbus, starting as its chief business officer in ...

View Article


At $300M Kardigan startup, former MyoKardia team unveils its first drug, and...

When some former MyoKardia execs reunited with $300 million for a new "heart health" biotech earlier this year, they were tight-lipped about their in-licensed clinical-stage assets. The company ...

View Article


What FDA, NIH hearings say about Trump drug, health policy

President Donald Trump's nominees for NIH director and FDA commissioner sailed through their respective confirmation hearings this week, facing few difficult questions and offering few controversial...

View Article

How bluebird's buyout offer went from $100M upfront to $29M

Bluebird bio went from a high-flying $10 billion company in 2018 during the heyday of gene therapy to being sold for a measly $29 million upfront in a fire sale last month. But it almost ...

View Article

Bayer eyes capital raise as it grapples with Monsanto cases

Bayer is asking shareholders to authorize a potential equity offer that would allow it to quickly raise billions of euros to deal with ongoing Monsanto litigation. The company requested an equity...

View Article


FDA approves Neurotech therapy for rare eye disease 

The FDA on Thursday approved Neurotech Pharmaceuticals’ cell therapy for an eye disease known as macular telangiectasia type 2, which causes central vision to become distorted and get worse over time ...

View Article

Start of 2025 comes with generic drug price decreases, several major...

More generic drug prices decreased than increased in January, a new report from 46Brooklyn found. The report said for every generic drug price increase in January, 1.3 generic drugs saw their ...

View Article

FDA and NIH nominees sail through Senate hearings; Tariffs’ early impact on...

Welcome back to Endpoints Weekly! This week was another busy one in DC, with two Senate hearings for Trump’s picks to lead the NIH and FDA, more actions from the Department of Government Efficiency,...

View Article


Sun Pharma to acquire Checkpoint Therapeutics and its anti-PD-L1 antibody

After months of searching for a partner for its recently approved cancer drug, Checkpoint Therapeutics has instead secured a buyer. India's Sun Pharma is acquiring the immuno-oncology biotech for $4.10...

View Article


Novo Nordisk’s CagriSema shows 15.7% weight loss in second pivotal trial

Novo Nordisk’s CagriSema demonstrated weight loss of 15.7% in patients with both obesity and type 2 diabetes who took the drug for more than a year, the company said Monday. ...

View Article

Arrowhead reveals small batch of open-label data for 'non-core' kidney drug

Arrowhead Pharmaceuticals on Monday shared new open-label data in about a dozen patients for a program designed to improve certain kidney disease outcomes by targeting complement pathways. The program,...

View Article

Trevi Therapeutics stock soars on Phase 2a chronic cough data

Trevi Therapeutics’ chronic cough drug reduced patients’ 24-hour cough frequency by 57% compared to placebo in a Phase 2a trial, exceeding investors’ expectations. The company’s stock {$TRVI} soared...

View Article

J&J, Protagonist outline first IBD win for potential immunological blockbuster

Johnson & Johnson and Protagonist Therapeutics have bet their oral IL-23 drug will be an immunology blockbuster, and they are now one step closer to that goal. The companies said Monday that the...

View Article


Mired in low expectations, Novo braces for upcoming CagriSema head-to-head trial

Novo Nordisk’s late-stage weight loss data showed CagriSema performed below analysts’ expectations. It's the second late-stage clinical letdown for the candidate, and the findings mean it is more vital...

View Article

FDA blocks drug and device reviewers from taking HHS' buyout offer

The FDA told staff on Monday that reviewers of medical products and inspectors of manufacturing facilities cannot take the buyout offer circulated on Friday from HHS that would've provided as much as...

View Article


#AAD25 roundup: Data from Amgen, Bristol Myers, J&J, Alumis and more

At this year’s American Academy of Dermatology annual meeting, companies like Amgen, Bristol Myers Squibb and Alumis took the stage to report the latest on their dermatology candidates. Here are the...

View Article

Beam shares promising first clinical data on gene editing treatment

Beam Therapeutics said its experimental gene editing treatment helped lower levels of mutant proteins and increase levels of corrected proteins in nine people with a lung disease called alpha-1...

View Article


Emergent sells once-troubled Baltimore site to Syngene

Emergent BioSolutions is selling a manufacturing site in Baltimore — which has a history of contaminated Covid-19 vaccines — for $36.5 million to India-headquartered CDMO Syngene. This purchase marks...

View Article

Federal judge denies preliminary injunction in tirzepatide compounding case

Compounding pharmacies faced a major setback in their case over the FDA’s decision to remove the obesity drug tirzepatide from its official shortage list. The US District Court for the Northern...

View Article

BioNTech's shares dip after posting lukewarm revenue guidance

BioNTech has forecast lackluster sales for 2025 despite ending last year on a relatively strong note, causing the drugmaker’s shares to slide about 2% on Monday. The Covid-19 vaccine maker said it...

View Article
Browsing all 3012 articles
Browse latest View live